In recent years, cancer therapies have often fallen short of expectations, with tumors developing resistance to medication. One such example is alpelisib, a drug approved for use in Switzerland as a treatment for advanced breast cancer.

However, a research group at the Department of Biomedicine of the University of Basel has made a breakthrough in understanding the reasons behind this resistance, publishing their findings in the journal Cell Reports Medicine.

For patients suffering from advanced and metastatic breast cancer, effective treatment options are limited. The PI3K signaling pathway is frequently overactive in breast cancer due to mutations that encourage tumor growth.